Published in TB and Outbreaks Week, December 9th, 1996
"Interrupting the administration of a protease inhibitor has the potential for inducing resistance to the drug and possibly to other agents in the protease inhibitor class of drugs, and also has a potential detrimental effect on a patient's clinical status," Elsa Villarino and Rick O'Brien of the CDC's Division of TB Elimination wrote in the winter issue of TB Notes ("The Use of HIV Protease Inhibitors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week